Imexpharm Corporation (HOSE:IMP)
Vietnam · Delayed Price · Currency is VND 35,100
+100 (0.29%)
At close: Nov 3, 2026
Imexpharm Financials Overview
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,292,869 | 2,441,085 | 2,205,120 | 1,994,037 | 1,643,707 | 1,266,597 |
Revenue Growth | -6.50% | 10.70% | 10.59% | 21.31% | 29.77% | -7.51% |
Gross Profit Gross Profit Growth | 1,104,773 | 1,159,077 | 1,023,486 | 983,973 | 819,555 | 596,940 |
Operating Income Operating Income Growth | 463,337 | 462,435 | 415,158 | 381,047 | 296,500 | 234,072 |
Net Income Net Income Growth | 320,659 | 304,389 | 275,862 | 277,778 | 183,844 | 173,513 |
Earnings Per Share EPS Growth | 2082.08 | 1976.44 | 1791.21 | 1803.65 | 1193.64 | 1126.63 |
EPS Growth | 0.54% | 10.34% | -0.69% | 51.11% | 5.95% | -6.15% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 522,557 | 401,296 | 303,983 | 199,201 | 390,145 | 383,726 |
Total Debt Total Debt Growth | 211,605 | 212,779 | 86,122 | 49,422 | 94,980 | 263,795 |
Net Cash (Debt) Net Cash Growth | 310,952 | 188,516 | 217,862 | 149,779 | 295,165 | 119,931 |
Net Cash Growth | 1263.84% | -13.47% | 45.46% | -49.26% | 146.11% | 568.18% |
Net Cash Per Share Net Cash Per Share Growth | 2019.05 | 1224.06 | 1414.60 | 972.53 | 1916.53 | 778.71 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 388,395 | 54,171 | 216,268 | -39,535 | 378,603 | 234,881 |
Capital Expenditures CapEx Growth | -37,788 | -26,879 | -96,771 | -63,530 | -99,353 | -52,857 |
Free Cash Flow Free Cash Flow Growth | 350,607 | 27,292 | 119,497 | -103,064 | 279,250 | 182,024 |
Free Cash Flow Growth | - | -77.16% | - | - | 53.41% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 48.18% | 47.48% | 46.41% | 49.35% | 49.86% | 47.13% |
Operating Margin | 20.21% | 18.94% | 18.83% | 19.11% | 18.04% | 18.48% |
Pretax Margin | 20.12% | 18.28% | 18.33% | 18.92% | 17.73% | 18.86% |
Profit Margin | 13.98% | 12.47% | 12.51% | 13.93% | 11.19% | 13.70% |
FCF Margin | 15.29% | 1.12% | 5.42% | -5.17% | 16.99% | 14.37% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 500.000 | - | 500.000 | 454.546 | 432.901 | 649.351 |
Dividend Per Share Growth | 20.00% | - | 10.00% | 5.00% | -33.33% | 0% |
Dividend Yield | 1.43% | - | 1.06% | 1.77% | 1.66% | 1.93% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.86 | 26.56 | 26.24 | 14.26 | 21.83 | 29.89 |
Forward PE | 15.23 | 22.97 | 20.30 | 11.68 | 19.00 | 21.00 |
P/FCF Ratio | 15.42 | 296.26 | 60.57 | - | 14.37 | 28.50 |
PS Ratio | 2.36 | 3.31 | 3.28 | 1.99 | 2.44 | 4.10 |